Form 4: Forte Biosciences CFO Antony A. Riley Reports Stock Transactions

Forte Biosciences CFO Antony A. Riley reports the acquisition and disposal of company stock and restricted stock units on October 1, 2024.

Summary

• On October 1, 2024, Antony A. Riley, CFO of Forte Biosciences, executed transactions involving the company's stock and restricted stock units (RSUs).
• Riley acquired 375 shares of common stock upon the vesting of RSUs at a price of $0.
• He also disposed of 133 shares of common stock at a price of $5.16.
• Following these transactions, Riley directly owns 8,262 shares of Forte Biosciences common stock and 3,375 RSUs.
• The reported number of securities has been adjusted to reflect the Issuer's 1-for-25 reverse stock split effected on August 28, 2024.
• The RSUs vest in sixteen quarterly installments, contingent upon Riley's continued service to the company.

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting required insider transactions. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gauge management's sentiment about the company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
• The vesting of RSUs incentivizes the CFO to remain with the company.

Key Dates